Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

• Status: Completed
• Trial end date: 2006-05-19
• Target enrollment: 0
• Participant gender: All

Summary

This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion criteria:

• Patients must have melanoma that has spread beyond the original location and has not yet been treated.

• Tissue from the spreading melanoma should have been tested to confirm it is melanoma.

Exclusion criteria:

• Patients having hepatitis or HIV infection.

• Taking corticosteroids.

• Patients with the primary site being occular melanoma or patients with melanoma of the brain.